About Research at UPMC Hillman Cancer Center

UPMC Hillman Cancer Center is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center - a highly prestigious classification for cancer centers in the U.S. We are the preeminent institution in western Pennsylvania for providing cancer care; conducting basic, translational, clinical, and population science research; and educating the next generation of cancer researchers and physicians.

Image of providers talking and looking at computer screen.

We have more than 300 researchers who collaborate with our clinicians to advance the most promising laboratory studies into novel clinical trials in order to provide patients with early access to new and innovative treatments.

The nationally and internationally renowned research at UPMC Hillman Cancer Center includes a range of disciplines, from cancer prevention and early detection to novel therapeutic discovery, survivorship, and end-of-life care.

We are also dedicated to the education and training of the next generation of cancer researchers and physicians, as well as the ongoing recruitment of world-renowned scientists.

As the only NCI-designated Comprehensive Cancer Center in western Pennsylvania, UPMC Hillman Cancer Center is dedicated to excellence for our patients, and we are working to make vast strides in the global effort to reduce the burden of cancer.

Learn More About

Recent News

John Byrd Named Director of UPMC Hillman Cancer Center

John C. Byrd, MD, is an internationally acclaimed physician scientist in hematologic malignancies with nearly three decades of distinguished experience in innovative research, superior patient care, and educational excellence. He will assume overall responsibility for all aspects of cancer-related basic, translational, and clinical research and education at both the University of Pittsburgh and UPMC Hillman in Nov. 2025.

Trial Improves Survival for Patients with Colorectal Cancer

A clinical trial led by UPMC Hillman researchers is the first to show that an immunotherapy-based, chemotherapy-free treatment can extend the lives of people with metastatic colorectal cancer who have exhausted prior standard chemotherapy options.

Announcing Dan Zandberg as AD for Clinical Research

Dr. Zandberg will work closely with Clinical Research Service (CRS) leadership and staff to roll out new initiatives designed to enhance our clinical trial accruals and portfolio management.

Learn more about the latest news and accomplishments from UPMC Hillman Cancer Center.